This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_PANCREAS_DUCTAL_EXALLC for full statistics.
Ductal carcinoma of pancreas
C3_PANCREAS_DUCTAL
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
220 |
4. Check minimum number of eventsNone |
220 |
5. Include endpointsNone |
220 |
6. Filter based on genotype QC (FinnGen only) |
220 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Ductal carcinoma of pancreas
based on the number of shared cases.
Similar with more cases:
- Ductal carcinoma of pancreas, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of pancreas, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of digestive organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 220 | 96 | 124 |
| Unadjusted period prevalence (%) | 0.05 | 0.03 | 0.05 |
| Median age at first event (years) | 68.91 | 69.72 | 68.28 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 203
- Matched controls
- 2031
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
482.1
172.0
151
12
130
Kela drug reimbursment
Malignant tumour
103.0
148.1
174
111
8500/3-C25.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of pancreas, NOS
+∞
146.1
122
*
A09AA02
ATC
multienzymes (lipase, protease etc.)
179.9
136.6
133
21
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
208.9
132.7
127
16
JLC30
NOMESCO Finland
Pancreatoduodenectomy
469.3
121.4
110
5
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
126.4
108.7
111
19
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
41.8
87.8
113
59
C25.9
ICD-10 Finland
Malignant neoplasm: Pancreas, unspecified
150.5
86.5
87
10
A03FA01
ATC
metoclopramide; systemic, rectal
20.9
78.6
158
292
8500/3-C25.0
ICD-O-3
Infiltrating duct carcinoma, NOS, of head of pancreas
+∞
71.1
64
*
H02AB02
ATC
dexamethasone; systemic
19.9
71.0
123
145
WX302
NOMESCO Finland
Thoracal epidural anesthesy
34.1
68.2
91
47
L01BC06
ATC
capecitabine; oral
40.0
66.2
84
35
A04AA02
ATC
granisetron; systemic, transdermal
21.2
62.1
99
87
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
25.7
56.6
82
52
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
112.2
54.2
57
7
Z51.5
ICD-10 Finland
Palliative care
20.6
51.1
80
62
N02AA05
ATC
oxycodone; systemic
11.8
50.8
113
195
JAH01
NOMESCO Finland
Laparoscopy
25.7
47.0
67
38
K83.1
ICD-10 Finland
Obstruction of bile duct
98.3
43.0
46
6
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
15.7
41.0
71
67
UJK02
NOMESCO Finland
ERCP
32.1
40.1
53
22
R17
ICD-10 Finland
Hyperbilirubinaemia, with or without jaundice, not elsewhere classified
75.0
37.8
42
7
JN4AD
NOMESCO Finland
Body CT examination
11.9
37.5
75
95
C25.1
ICD-10 Finland
Malignant neoplasm: Body of pancreas
154.8
37.1
38
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
24.5
36.4
52
28
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
23.5
33.9
49
27
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
101.6
31.8
34
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
20.7
31.2
47
29
JKE98
NOMESCO Finland
Other transduodenal endoscopic operation on bile duct or ampulla of Vater
32.9
30.7
40
15
JKE18
NOMESCO Finland
Endoscopic internal drainage of bile duct
52.5
29.8
35
8
TPX10
NOMESCO Finland
Implantation of vascular injection port
17.1
29.1
47
35
R4190
NOMESCO Finland
Nutritional therapy
21.5
29.1
43
25
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
11.4
28.8
57
67
PHN73
NOMESCO Finland
Reconstruction of superior mesenteric or portal vein
+∞
26.6
25
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
5.2
26.6
124
471
JN4CD
NOMESCO Finland
Very extensive body CT
13.6
26.3
47
44
R50.9
ICD-10 Finland
Fever, unspecified
6.8
25.5
73
154
WZC30
NOMESCO Finland
Teaching
6.4
24.9
75
169
A04AA01
ATC
ondansetron; systemic, rectal
9.9
24.6
52
68
JL5SB
NOMESCO Finland
Endoscopic retrograd cholangiopancreaticography
27.8
24.4
33
14
D76
ICPC
Malignant neoplasm pancreas
257.9
23.1
23
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
7.9
23.0
57
96
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
12.8
22.1
40
38
JKE02
NOMESCO Finland
Transduodenal endoscopic incision of common bile duct orifice
38.6
21.7
27
8
C25.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of pancreas
232.9
21.0
21
*
B01AB10
ATC
tinzaparin; parenteral
8.3
20.9
49
75
A06AH03
ATC
naloxegol; oral
37.0
20.8
26
8
JN3BD
NOMESCO Finland
Extensive abdominal CT
6.4
20.7
60
125
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
23.9
20.6
29
14
JN4BD
NOMESCO Finland
Extensive body CT
5.8
20.4
65
152
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
14.4
19.4
33
27
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.8
19.4
76
223
B01AB05
ATC
enoxaparin; parenteral
4.0
19.2
109
452
L03AA02
ATC
filgrastim; parenteral
13.4
18.8
33
29
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
20.5
18.4
27
15
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
8.6
18.3
41
58
A02BC02
ATC
pantoprazole; systemic
4.5
17.2
170
1088
C25
ICD-10 Finland
Malignant neoplasm of pancreas
+∞
16.9
16
*
JJ1CE
NOMESCO Finland
Liver, bile duct and pancreas endoscopic ultrasound examination
184.5
16.8
17
*
TPH07
NOMESCO Finland
Cathetrisation of artery
5.1
16.4
57
144
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
7.3
16.1
40
66
C25.2
ICD-10 Finland
Malignant neoplasm: Tail of pancreas
65.4
16.0
18
*
JLC40
NOMESCO Finland
Total pancreatoduodenectomy
+∞
15.8
15
*
JLC10
NOMESCO Finland
Distal pancreatectomy
49.1
15.3
18
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.0
15.2
53
133
XJD02
NOMESCO Finland
Peroral endoscopic ultrasonography
34.7
15.1
19
6
K83.0
ICD-10 Finland
Cholangitis
22.0
14.1
20
10
WX402
NOMESCO Finland
General anaesthesia
4.0
14.0
63
203
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
13.9
75
280
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
36.9
13.7
17
5
JN3AD
NOMESCO Finland
Abdominal CT examination
5.4
13.4
42
93
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
43.2
13.4
16
*
JMA10
NOMESCO Finland
Transabdominal total splenectomy
34.5
12.8
16
5
ZX120
NOMESCO Finland
Intravenous
4.7
12.3
44
112
JK3BT
NOMESCO Finland
Catherisation of bile duct with X-ray guidance
37.4
11.4
14
*
WW500
NOMESCO Finland
Blood transfusion
7.0
11.4
28
45
A04AA55
ATC
palonosetron, combinations; systemic
9.5
11.4
23
27
R10.1
ICD-10 Finland
Pain localized to upper abdomen
3.5
10.9
57
201
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
9.3
10.9
22
26
A10AE04
ATC
insulin glargine; parenteral
4.6
10.8
39
100
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
12.2
10.8
19
17
JL1AT
NOMESCO Finland
Biopsy of pancreas with ultrasound guidance
115.7
10.5
11
*
JK3NB
NOMESCO Finland
Percutaneous transhepatic cholangiography
42.3
10.1
12
*
JAH00
NOMESCO Finland
Laparotomy
9.5
10.0
20
23
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
6.8
9.7
24
39
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.5
9.7
51
179
1CD01
NOMESCO Finland
NA
31.7
9.5
12
*
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
12.3
9.2
16
14
D13.6
ICD-10 Finland
Benign neoplasm: Pancreas
38.6
9.1
11
*
JKE25
NOMESCO Finland
Endoscopic external drainage of bile duct
38.6
9.1
11
*
N05BA06
ATC
lorazepam; systemic, sublingual
5.8
9.0
25
48
L03AA13
ATC
pegfilgrastim; parenteral
5.8
9.0
25
48
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
8.9
118
728
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
8.9
8.8
18
22
A04AD12
ATC
aprepitant; systemic
8.9
8.8
18
22
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
9.7
8.7
17
19
N02AX02
ATC
tramadol; systemic, rectal
2.4
8.5
107
636
WX610
NOMESCO Finland
Patient controlled analgesia
93.8
8.5
9
*
8500/3-C25.1
ICD-O-3
Infiltrating duct carcinoma, NOS, of body of pancreas
+∞
8.4
8
*
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
6.0
8.3
22
40
WX892
NOMESCO Finland
Monitored bed care
3.9
8.2
34
99
K85.9
ICD-10 Finland
Acute pancreatitis, unspecified
12.4
8.2
14
12
ZX122
NOMESCO Finland
Intra-arterial
18.1
8.2
12
7
E14.9
ICD-10 Finland
Unspecified diabetes mellitus, without complications
11.5
7.9
14
13
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
12.5
7.7
13
11
R18
ICD-10 Finland
Ascites
9.4
7.7
15
17
SPAT1109
SPAT
Analgesia with portable analgesic pump
19.3
7.7
11
6
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.4
7.4
78
419
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
7.8
7.3
16
22
JK3NT
NOMESCO Finland
Percutaneous transhepatic dilatation of bileducts
+∞
7.3
7
*
E89.1
ICD-10 Finland
Postprocedural hypoinsulinaemia
+∞
7.3
7
*
8500/3-C25.2
ICD-O-3
Infiltrating duct carcinoma, NOS, of tail of pancreas
+∞
7.3
7
*
JK4ZT
NOMESCO Finland
Percutaneous transhepatic implantation of bile duct prothesis
41.5
6.8
8
*
JKE22
NOMESCO Finland
Endoscopic extraction of foreign body from bile duct
41.5
6.8
8
*
103
Kela drug reimbursment
Diabetes, insulin-treated
2.3
6.6
75
414
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
7.0
6.5
15
23
JL2AT
NOMESCO Finland
Cytology of pancreas with ultrasound guidance
72.0
6.5
7
*
K90.3
ICD-10 Finland
Pancreatic steatorrhoea
18.7
6.3
9
5
WX004
NOMESCO Finland
Patient-controlled sedation
18.7
6.3
9
5
A06AD11
ATC
lactulose; oral
2.8
6.3
42
172
N05AD01
ATC
haloperidol; systemic
6.7
6.3
15
24
JN1BD
NOMESCO Finland
Extensive CT examination of upper part of abdomen
+∞
6.3
6
*
K86.3
ICD-10 Finland
Pseudocyst of pancreas
27.6
6.3
8
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
112
55
40.44
158.31
1.6
1.5
111.47
246.77
ug/g
4.08
52
34
169
621
8.43
47.42
7.7
2.6
48.24
56.90
u/l
1.02
161
574
35
24
17.15
39.98
1.3
1.3
—
—
—
0
0
84
190
6.53
38.34
9.4
2.7
448.62
32.40
u/l
0.57
79
161
100
291
5.47
33.97
11.7
6.8
105.09
104.17
mmol/l
1.48
100
284
29
27
12.22
27.46
1.6
2.4
3.57
9.88
nmol/l
0.53
29
27
59
143
5.27
23.98
1.6
1.5
—
—
—
0
0
69
226
3.99
18.68
1.9
2.0
—
—
—
0
0
68
223
3.97
18.34
2.0
1.9
—
—
—
0
0
159
897
3.79
18.30
6.9
4.1
—
—
—
0
0
177
1073
4.32
18.23
39.3
10.0
3.91
4.17
e9/l
0.94
164
943
83
314
3.64
18.10
2.0
1.9
—
—
—
0
0
130
670
3.30
16.85
13.3
3.4
2.30
2.35
mmol/l
3.40
124
580
156
913
3.44
16.00
9.7
5.9
1.18
1.21
mmol/l
4.35
150
820
70
255
3.56
15.93
10.5
7.2
1.54
1.21
mmol/l
0.45
62
211
158
992
3.10
13.19
10.0
6.8
1.18
1.21
mmol/l
4.34
134
834
76
331
2.98
12.47
1.9
2.1
7.96
12.99
umol/l
10.39
76
296
31
76
4.58
12.05
8.8
3.7
3.80
3.94
mmol/l
1.24
31
70
77
346
2.89
11.85
2.2
2.0
30.65
29.31
s
1.12
77
335
68
294
2.90
11.16
1.7
2.2
13.26
22.52
%
10.15
56
255
23
47
5.35
11.00
2.9
3.0
49.64
36.33
umol/l
0.76
18
42
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
26
68
4.20
9.26
3.3
2.1
0.21
0.36
u/ml
1.96
11
33
24
60
4.37
9.05
2.1
1.5
—
—
—
0
0
87
471
2.40
8.72
3.5
2.4
—
—
—
0
0
10
10
10.43
8.70
1.6
1.5
24.20
28.40
umol/l
—
10
10
36
130
3.12
7.95
1.8
1.4
—
—
—
0
0
150
1832
0.43
7.30
3.6
5.0
1.37
1.45
mmol/l
1.28
134
1652
152
1840
0.44
6.93
3.7
5.1
4.25
4.54
mmol/l
2.31
139
1673
33
125
2.93
6.68
5.3
6.5
26.15
24.97
mmol/l
1.64
33
125
17
41
4.41
6.68
4.8
3.2
5.47
4.90
kpa
2.99
17
41
159
1883
0.44
6.45
4.0
5.7
2.43
2.65
mmol/l
2.11
142
1704
147
1788
0.46
6.28
3.4
4.5
1.33
1.29
mmol/l
0.29
132
1607
109
739
1.94
5.49
4.0
3.2
—
—
—
0
0
80
490
1.99
5.40
2.0
1.9
3.14
3.23
mg/l
0.12
74
426
12
27
4.64
5.10
1.9
1.7
18.01
18.31
ug/l
0.02
12
27
40
192
2.32
5.01
4.3
7.0
1.48
1.25
mmol/l
0.79
40
186
20
67
3.18
4.97
1.2
1.2
—
—
—
0
0
138
1678
0.52
4.86
3.6
4.6
1.99
1.99
mu/l
0.01
123
1492
152
1783
0.52
4.45
49.3
15.3
84.15
76.31
ml/min/173m2
5.91
143
1482
26
109
2.57
4.34
2.0
2.9
1.43
1.22
%
0.37
26
109
12
31
4.04
4.31
1.1
1.5
—
—
—
0
0
8
10
8.25
4.09
1.7
2.4
73.75
67.30
nmol/l
—
8
10
37
190
2.14
3.92
2.9
3.8
5.69
5.77
kpa
0.19
37
184
85
579
1.76
3.88
3.5
3.2
0.33
0.57
e6/l
0.77
68
438
13
39
3.48
3.82
1.1
1.7
—
—
—
0
0
16
55
3.06
3.82
1.1
1.6
—
—
—
0
0
61
380
1.84
3.73
4.2
3.9
52.87
266.20
ng/l
1.83
53
324
16
56
3.00
3.71
1.1
1.6
—
—
—
0
0
36
187
2.11
3.71
3.0
3.9
2.56
2.22
mmol/l
0.22
28
147
8
14
5.88
3.37
1.1
1.4
—
—
—
0
0
163
1836
0.57
3.17
4.6
5.1
6.55
6.11
mmol/l
3.31
157
1654
31
162
2.06
3.14
2.9
3.1
4.60
4.38
kpa
0.16
31
155
9
21
4.42
3.03
1.1
1.4
—
—
—
0
0
72
500
1.65
2.93
4.4
4.0
0.00
0.00
estimate
0.00
21
172
14
53
2.75
2.85
1.3
1.3
—
—
—
0
0
31
517
0.53
2.71
2.1
3.1
0.77
0.76
ug/l
0.01
21
349
110
1340
0.64
2.68
3.2
3.8
15.19
14.92
pmol/l
0.49
97
1183
7
16
4.48
2.49
1.0
1.0
—
—
—
0
0
11
41
2.77
2.31
1.5
1.6
—
—
—
0
0
11
41
2.77
2.31
1.5
1.6
—
—
—
0
0
0
62
0.00
2.26
0.0
1.4
—
3.38
—
0
47
56
388
1.59
2.25
4.7
4.2
1.02
1.02
kg/l
0.27
12
60
6
14
4.37
2.16
1.3
3.4
—
—
—
0
0
12
50
2.48
2.06
1.6
1.5
—
—
—
0
0
49
337
1.58
2.02
3.7
3.0
3.11
1.72
e6/l
0.33
25
191
7
21
3.41
1.98
1.0
1.7
—
—
—
0
0
21
116
1.90
1.86
2.0
1.7
—
—
—
0
0
28
173
1.71
1.74
7.4
4.1
1.21
1.22
mmol/l
0.20
28
153
0
46
0.00
1.73
0.0
1.3
—
—
—
0
0
0
47
0.00
1.72
0.0
1.3
—
2.43
—
0
11
8
31
2.64
1.67
1.3
1.7
—
—
—
0
0
100
824
1.39
1.62
4.2
3.9
18.83
45.62
ng/l
3.30
77
627
10
44
2.33
1.55
1.2
1.6
—
—
—
0
0
9
37
2.49
1.50
1.2
1.6
—
—
—
0
0
49
361
1.46
1.46
3.5
2.9
0.83
0.90
e6/l
0.10
25
212
7
28
2.55
1.46
1.7
1.6
—
—
—
0
0
71
874
0.72
1.43
3.7
5.2
2.35
2.59
ug/l
0.18
64
780
86
704
1.36
1.41
4.6
4.0
—
—
—
0
0
7
29
2.46
1.40
4.7
3.2
63.14
60.38
%
—
7
29
0
37
0.00
1.35
0.0
1.3
—
43.30
—
0
5
36
253
1.51
1.35
26.3
8.0
—
—
—
0
0
5
20
2.53
1.15
1.0
1.3
121.10
316.13
u/l
—
5
20
10
51
2.01
1.13
1.1
1.2
—
—
—
0
0
106
918
1.30
1.12
5.2
5.1
0.00
0.00
estimate
0.00
22
182
11
59
1.91
1.09
1.1
1.3
—
—
—
0
0
107
932
1.29
1.07
4.2
3.8
0.00
0.00
estimate
0.00
22
172
12
69
1.78
0.98
1.3
1.3
—
—
—
0
0
6
120
0.49
0.96
1.2
1.9
—
—
—
0
0
88
756
1.27
0.96
2.2
2.1
63.37
76.72
nmol/l
4.90
83
652
170
1802
0.75
0.96
7.3
6.4
44.23
40.78
mmol/mol
3.12
164
1654
9
52
1.76
0.93
1.1
1.2
—
—
—
0
0
6
29
2.10
0.90
1.8
1.5
—
—
—
0
0
187
1951
0.72
0.88
64.4
19.5
69.63
80.91
umol/l
9.08
187
1951
6
30
2.03
0.87
1.8
1.5
—
—
—
0
0
103
911
1.25
0.86
4.2
3.8
0.00
0.00
estimate
0.00
23
182
6
31
1.96
0.85
1.0
1.2
—
96.17
—
0
6
6
32
1.90
0.82
2.2
3.4
105.67
104.97
mmol/l
—
6
32
10
58
1.76
0.81
1.7
1.7
—
—
—
0
0
29
218
1.38
0.80
7.4
3.5
—
—
—
0
0
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
0
27
0.00
0.78
0.0
1.2
—
5.40
—
0
10
9
54
1.69
0.75
1.1
1.4
—
—
—
0
0
6
107
0.55
0.74
1.2
1.3
—
36.13
—
0
10
7
38
1.87
0.74
1.1
1.6
—
—
—
0
0
5
26
1.94
0.71
1.0
1.8
—
—
—
0
0
5
26
1.94
0.71
1.0
1.8
—
—
—
0
0
5
26
1.94
0.71
1.0
1.8
—
—
—
0
0
61
704
0.82
0.66
4.1
4.5
20.13
21.37
%
0.31
30
350
5
29
1.74
0.64
2.0
1.5
—
—
—
0
0
5
29
1.74
0.64
2.0
1.5
—
—
—
0
0
5
29
1.74
0.64
2.0
1.5
—
—
—
0
0
5
29
1.74
0.64
2.0
1.5
—
—
—
0
0
13
186
0.68
0.62
1.1
1.4
—
—
—
0
0
5
30
1.68
0.62
1.4
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
35.43
—
0
10
0
21
0.00
0.60
0.0
1.0
—
467.64
—
0
11
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
0
23
0.00
0.58
0.0
1.1
—
—
—
0
0
0
23
0.00
0.58
0.0
1.2
—
1.17
—
0
6
10
65
1.56
0.56
1.7
1.9
—
—
—
0
0
34
280
1.25
0.53
19.1
21.9
1.95
1.36
inr
—
6
34
46
533
0.83
0.51
1.7
1.7
1.30
1.35
mmol/l
0.12
39
432
47
403
1.21
0.51
1.7
1.7
1521.29
1235.42
nmol/l
1.17
40
301
11
78
1.43
0.44
1.9
3.0
—
—
—
0
0
5
31
1.63
0.43
1.0
1.1
—
—
—
0
0
5
31
1.63
0.43
1.0
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
132
1388
0.88
0.39
2.9
4.2
18.37
13.30
mm/h
2.42
123
1247
5
36
1.40
0.38
1.4
1.2
—
—
—
0
0
15
124
1.23
0.24
7.9
9.3
24.67
24.58
mmol/l
0.06
15
117
0
11
0.00
0.21
0.0
6.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
9.38
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
1.05
—
0
8
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
87
913
0.92
0.20
3.0
2.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
79
827
0.93
0.17
2.1
2.0
90.87
93.14
pmol/l
0.19
63
420
20
219
0.90
0.11
1.3
1.4
—
—
—
0
0
6
57
1.05
0.08
1.3
1.7
—
—
—
0
0
70
682
1.04
0.06
3.2
4.0
8.37
8.75
mg/mmol
0.03
47
424
13
120
1.09
0.05
1.6
3.2
1.50
2.12
mmol/l
—
6
93
36
368
0.97
0.02
1.3
1.2
10.17
1.44
u/ml
0.43
13
97
160
1592
1.02
0.01
52.4
17.0
34.15
39.59
%
7.23
96
1054
68
678
1.00
0.00
2.2
3.1
915.15
1156.67
ng/l
0.38
60
573
18
177
1.02
0.00
1.3
1.9
1.28
1.62
%
1.23
13
145
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
7
78
0.89
0.00
1.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
0.00
0.0
1.2
—
126.17
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
9.66
—
0
5
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
0.00
0.0
1.2
—
107.80
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
5
51
0.98
0.00
1.8
1.4
—
—
—
0
0
5
55
0.91
0.00
1.2
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_PANCREAS_DUCTAL – Ductal carcinoma of pancreas
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).